AUTHORS
Kaustav Mukherjee, PhD, Sanjana Pillay, PhD2, James Bieker, PhD3
AFFILIATIONS
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States
ABSTRACT
Congenital Dyserythropoietic Anemia Type IV is a rare erythroid disease characterized by ineffective erythropoiesis and hemolytic anemia that causes patients to be transfusion dependent for life. CDA IV is caused by a heterozygous dominant mutation in the erythroid transcription factor EKLF/KLF1 (denoted as EKLF+/E325K), that affects the expression of both EKLF target and non-target genes. Studies using CDA IV BEL-A cells show that the erythroid proteome and transcriptome are drastically altered contributing significantly to ineffective erythropoiesis and disease progression. However, the underlying transcriptional mechanisms affected by the E325K mutation causing these global alterations remain elusive. Thus, we used ChIP-seq to assay the global chromatin occupancy of EKLF and other transcription factors in WT and CDA IV BEL-A cells, and examined their effects on transcription by RNA Polymerase II (RNAP2) as well as chromatin state and histone modifications.
First, we found that the E325K mutation alters EKLF DNA binding preferences such that it is no longer able to bind efficiently to the regulatory regions of many important erythroid targets in CDA IV. Surprisingly, this loss of binding occurs despite the presence of WT EKLF in the CDA IV cells. This correlates with reduced chromatin accessibility assayed by ATAC-seq, and reduced binding of the transcription co-activators CBP and BRD4. RNAP2 Ser5p levels are also lower in CDA IV and its traveling ratio is significantly reduced suggesting inefficient transition from pausing to elongation. Consistent with this, the elongation specific histone mark H3K36me3 is reduced at these genes whereas there is an increase in facultative heterochromatin mark H3K27me3 suggesting increased silencing.
Second, there are several ectopically activated genes in CDA IV whose expression likely interferes with terminal erythroid maturation and efficient cell cycle progression. EKLF is ectopically bound at these genes’ promoters and enhancers due to the presence of higher affinity binding sites for the E325K mutant at these locations. This leads to overall higher RNAP2 occupancy in CDA IV but the transition from pausing to elongation is still inefficient as seen by a higher traveling ratio at ectopic genes. CDA IV ectopic genes also have higher CBP at both promoters and enhancers correlating directly with EKLF binding, but higher BRD4 binding is only seen at enhancers. Consequently, treatment of CDA IV cells with a specific BET inhibitor targeting CBP rescues cell proliferation during later stages of erythroid maturation, but has no effect on WT BEL-A cell growth and maturation. This suggests that inhibiting ectopic gene expression by targeting CBP can improve erythropoiesis in CDA IV.
Third, the RNAP2 pausing and elongation patterns at ectopic genes in CDA IV are reminiscent of the patterns obtained after depletion of specific subunits of the Integrator complex. The Integrator complex is a major RNAP2 elongation regulator, and multiple important subunits such as INTS12 and INTS11 have reduced protein levels in CDA IV BEL-A cells. Global binding analysis of INTS11 and INTS12 by ChIP-seq shows that at genes that lose EKLF binding in CDA IV, INTS12 is reduced at the TSS and enhancers whereas INTS11 binding is specifically reduced at the TSS. In contrast, at ectopic genes, INTS12 is reduced at the TSS whereas INTS11 is increased at enhancers. Thus, Integrator subunit protein expression is affected in CDA IV, and this also changes their global occupancy patterns likely culminating in inefficient RNAP2 elongation at both EKLF erythroid targets and ectopic genes.
In conclusion, the CDA IV EKLF-E325K mutation changes EKLF binding patterns in BEL-A cells causing profound changes in transcription dynamics. A key mechanistic aspect affected by the mutation is the transition of RNAP2 from a paused to an elongating state. This defect is enabled by the altered occupancy of the bromodomain proteins CBP and BRD4, and specific subunits of the Integrator complex that ultimately affect the chromatin state and histone modifications. Targeting CBP with specific inhibitors partly rescues the proliferation defect in CDA IV erythroid differentiation indicating that targeting underlying mechanisms of ectopic gene activation can partially restore ineffective erythropoiesis in CDA IV. Thus, BET inhibitors targeting CBP or BRD4 can be explored as potential therapeutic approaches to treat CDA IV.
DISCLOSURES
Kaustav Mukherjee, PhD: No relevant conflicts of interest to declare.